phensuximide (Milontin)

Introduction

Tradename: Milontin.

Indications

seizures

Dosage

500-1000 mg PO BID/TID

Tabs: 500 mg

Pharmacokinetics

• rapidly absorbed
• metabolized in liver to active N-desmethyl derivative

elimination via liver

elimination via kidney

1/2life = 4 hours

protein binding = <5 %

elimination by hemodialysis = -

elimination by hemoperfusion = -

elimination by peritoneal dialysis = -

Adverse effects

• nausea/vomiting
• anorexia
• headache
• fatigue
• lethargy
• dizziness

• drug adverse effects of anticonvulsants

Drug interactions

• agents which increase phensuximide metabolism
  • carbamazepine
  • phenobarbital
  • phenytoin
  • primidone
• valproic acid may increase or decrease phensuximide concentration

• drug interaction(s) anticonvulsants with anti-bacterial agents
• drug interaction(s) anticonvulsants with statins

Laboratory

• specimen: serum, plasma (heparin, EDTA)
• methods: GLC, HPLC

More general terms

• succinimide
• anticonvulsant

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6839